Oxytocin and Social Cognition in Schizophrenia.

Trial Profile

Oxytocin and Social Cognition in Schizophrenia.

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Actual patient number 28 added as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Sep 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top